| Literature DB >> 26414837 |
Hitoshi Satomura1, Masanobu Nakajima1, Kinro Sasaki1, Satoru Yamaguchi1, Yasushi Domeki1, Masakazu Takahashi1, Hiroto Muroi1, Tsukasa Kubo1, Maiko Kikuchi1, Haruka Otomo1, Keisuke Ihara1, Hiroyuki Kato1.
Abstract
A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m(2) DOC plus 70 mg/m(2) CDDP on day 1 plus 700 mg/m(2) 5-FU on days 1-5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.Entities:
Keywords: Cisplatin; Docetaxel; Esophagus; Fluorouracil; Phase I
Mesh：
Substances：
Year: 2015 PMID： 26414837 PMCID： PMC4587522 DOI： 10.9738/INTSURG-D-14-00233.1
Source DB: PubMed Journal: Int Surg ISSN： 0020-8868